126 related articles for article (PubMed ID: 37212125)
1.
Zhao J; Liu J; Liu S; Tian S; Yuan H; Li S
Epigenomics; 2023 Mar; 15(6):369-383. PubMed ID: 37212125
[No Abstract] [Full Text] [Related]
2. Tumor suppressor miR-139-5p targets Tspan3 and regulates the progression of acute myeloid leukemia through the PI3K/Akt pathway.
Zhang R; Tang P; Wang F; Xing Y; Jiang Z; Chen S; Meng X; Liu L; Cao W; Zhao H; Ma P; Chen Y; An C; Sun L
J Cell Biochem; 2019 Mar; 120(3):4423-4432. PubMed ID: 30367526
[TBL] [Abstract][Full Text] [Related]
3. Regulatory role of RBM39 in acute myeloid leukemia: Mediation through the PI3K/AKT pathway.
Zhang X; Yang L; Liu X; Nie Z; Liu M; Wang T; Lu Y; Pan Y; Zhan Y; Wang Z; Luo J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119607. PubMed ID: 37852323
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype.
Liu Y; Chen Y; Liu Y; Li M; Zhang Y; Shi L; Yang L; Li T; Li Y; Jiang Z; Liu Y; Wang C; Wang S
J Transl Med; 2022 Dec; 20(1):612. PubMed ID: 36550462
[TBL] [Abstract][Full Text] [Related]
5. ZEB1 serves as an oncogene in acute myeloid leukaemia via regulating the PTEN/PI3K/AKT signalling pathway by combining with P53.
Li L; Feng Y; Hu S; Du Y; Xu X; Zhang M; Peng X; Chen F
J Cell Mol Med; 2021 Jun; 25(11):5295-5304. PubMed ID: 33960640
[TBL] [Abstract][Full Text] [Related]
6. miR-338-3p Plays a Significant Role in Casticin-Induced Suppression of Acute Myeloid Leukemia via Targeting PI3K/Akt Pathway.
Yu K; Wang J; Hou J; Zhang L; Liang H
Biomed Res Int; 2022; 2022():9214130. PubMed ID: 35765408
[TBL] [Abstract][Full Text] [Related]
7. CXCL8 derived from mesenchymal stromal cells supports survival and proliferation of acute myeloid leukemia cells through the PI3K/AKT pathway.
Cheng J; Li Y; Liu S; Jiang Y; Ma J; Wan L; Li Q; Pang T
FASEB J; 2019 Apr; 33(4):4755-4764. PubMed ID: 30592634
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway.
Wang F; Yang L; Xiao M; Zhang Z; Shen J; Anuchapreeda S; Tima S; Chiampanichayakul S; Xiao Z
Sci Rep; 2022 Jul; 12(1):11444. PubMed ID: 35794161
[TBL] [Abstract][Full Text] [Related]
9. Circ_0009910 sponges miR-491-5p to promote acute myeloid leukemia progression through modulating B4GALT5 expression and PI3K/AKT signaling pathway.
Wu Y; Zhao B; Chen X; Geng X; Zhang Z
Int J Lab Hematol; 2022 Apr; 44(2):320-332. PubMed ID: 34709725
[TBL] [Abstract][Full Text] [Related]
10. Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
Liang X; Xia R
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34792179
[TBL] [Abstract][Full Text] [Related]
11.
Zhou JD; Li XX; Zhang TJ; Xu ZJ; Zhang ZH; Gu Y; Wen XM; Zhang W; Ji RB; Deng ZQ; Lin J; Qian J
Aging (Albany NY); 2019 May; 11(10):3376-3391. PubMed ID: 31147526
[No Abstract] [Full Text] [Related]
12. Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11.
Jiang D; Wu X; Sun X; Tan W; Dai X; Xie Y; Du A; Zhao Q
J Nanobiotechnology; 2022 Jan; 20(1):29. PubMed ID: 35012554
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells.
Liang H; Zheng QL; Fang P; Zhang J; Zhang T; Liu W; Guo M; Robinson CL; Chen SB; Chen XP; Chen FP; Zeng H
Sci Rep; 2017 Jan; 7():40361. PubMed ID: 28098170
[TBL] [Abstract][Full Text] [Related]
14. UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K/AKT activation.
Wang L; Zhao S; Wang Y; Liu J; Wang X
BMC Cancer; 2024 Apr; 24(1):497. PubMed ID: 38637730
[TBL] [Abstract][Full Text] [Related]
15. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
16. Davanone terpenoid inhibits cisplatin-resistant acute myeloid leukemia cancer cell growth by inducing caspase-dependent apoptosis, loss of mitochondrial membrane potential, inhibition of cell migration and invasion and targeting PI3K/AKT/MAPK signalling pathway.
Xiao Y; Deng T; Wang D
J BUON; 2020; 25(3):1607-1613. PubMed ID: 32862611
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
18. ROS play an important role in ATPR inducing differentiation and inhibiting proliferation of leukemia cells by regulating the PTEN/PI3K/AKT signaling pathway.
Feng Y; Hua X; Niu R; Du Y; Shi C; Zhou R; Chen FH
Biol Res; 2019 May; 52(1):26. PubMed ID: 31053167
[TBL] [Abstract][Full Text] [Related]
19. Prazosin inhibits the proliferation and survival of acute myeloid leukaemia cells through down-regulating TNS1.
Sun X; Yang S; Song W
Biomed Pharmacother; 2020 Apr; 124():109731. PubMed ID: 31954876
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y
Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
